Characteristic and Complication Patterns of Polycythaemia Vera: A Single Centre Experience

Rebin Mustafa  Othman; Ali Ibrahim   Mohammed

doi:10.56056/amj.2025.344

Authors

Rebin Mustafa Othman MBChB, HDH, KBMS Hematopathology Trainee, Hiwa Hospital, Hematopathology Department, Sulaymaniyah, Iraq
Ali Ibrahim Mohammed MBChB, FIBMS (Hematopathology), Assistant Professor at the University of Sulaimani, college of medicine, basic science department, Sulaymaniyah, Iraq

DOI:

https://doi.org/10.56056/amj.2025.344

Keywords:

Characteristics, Complications, Polycythemia Vera, Single Centre

Abstract

Background and objectives: In addition to being at risk for thrombosis and disease progression, patients with polycythemia vera frequently have a wide variety of clinical, demographic and laboratory presentations which vary according to the geographical area and ethnic groups. This study aimed at defining these variations in our locality and comparing it to other international studies.

Methods: This cross-sectional study was carried out from January 2022 to January 2023 at Hiwa Cancer Hospital, Sulaymaniyah City, with a total of 200 adult cases of already diagnosed and registered cases of polycythemia vera according to the 2016 WHO criteria. The overview of demographic profiles: the age distribution, gender prevalence, laboratory characteristics, and complications patterns of these cases were studied.

Results: From the total of 200 cases, 118 (59%) were males and 82 (41%) of them were females, the mean age (60.4 ± 12.4) year, with a range of (25–88), 47 (23.5%) patients were having complications, either thrombosis 19 (40.4%), acute myeloid leukemia progression, 8 (4%), or myelofibrosis 20 (42.6%), and 153 (76.5%) of patients did not show any complication, 104 (52%) had splenomegaly. There were significant associations between development of complications and certain parameters like: age, disease duration, leukocyte count, platelets, and hemoglobin levels, in a concordance way i.e., the higher the value of these parameters, the higher the risk of developing complications.

Conclusions: distinctive patterns of these parameters were identified in our locality and correlated to other geographical areas. Our findings showed the significance of understanding different patterns of patient characteristics andcomplications of polycythemia vera in different regions.

Downloads

Download data is not yet available.

References

Tefferi A, Barbui T. Polycythemia vera: 2024 updates on diagnosis, risk-stratification, and management. Am J Hematol. 2023;98(9):1465-1487.

Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study. Leukemia. 2013;27 (9):1874-1881.

Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. Am J Hematol. 2019;94 (1):133-143.

Szuber N, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL, et al. 3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups. Mayo Clin Proc. 2019;94(4):599–610.

Tsai TH, Yu LHL, Yu MS, Huang SH, Lin AJH, Lee K Der, et al. Real-world patient characteristics and treatment patterns of polycythemia vera in Taiwan between 2016 and 2017: a nationwide cross-sectional study. The Adv Hematol. 2023;4(4):288–98.

Eren R, Funda Sevinçolu B, Doan EE, Aydn D, Nizam N, Demirel N. How Does 2016 WHO Criteria for Polycythemia Vera Contribute to Our Daily Practice A Single-Center Study from Turkey. Int J Hematol Oncol Stem Cell Res. 2020;14 (4):232-236.

Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23 (10):2224-2232.

Moulard O, Mehta J, Fryzek J, Olivares R, Iqbal U, Mesa RA. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 2014;92 (4):289–97.

Mesa RA, Jamieson C, Bhatia R, et al. NCCN guidelines insights: myeloproliferative neoplasms, version 2.2018. J Natl Compr Canc Netw 2017; 15: 1193–1207.

Jackson Chornenki NL, Chai-Adisaksopha C, Leong DP, Siegal DM, Hillis CM. The real-world outcomes of treating Polycythemia Vera: Physician adherence to treatment guidelines. Leuk Res. 2018; 70:62–6.

Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014;55 55 (3):595–600.

Barbui T, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F, et al. To the editor: In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood. 2014;124 (19):3021-3.

Varghese C, Immanuel T, Ruskova A, Theakston E, Kalev-Zylinska ML. The epidemiology of myeloproliferative neoplasms in new zealand between 2010 and 2017: Insights from the new zealand cancer registry. Curr Oncol. 2021;28 (2):1544-1557.

Byun JM, Kim YJ, Youk T, Yang JJ, Yoo J, Park TS. Real world epidemiology of myeloproliferative neoplasms: a population-based study in Korea 2004–2013. Ann Hematol. 2017;96 (3):373-381.

Lim Y, Lee JO, Bang SM.Incidence, survival and prevalence statistics of classical myeloproliferative neoplasm in Korea. J Korean Med Sci 2016; 31: 1579–1585.

Bai J, Ai L, Zhang L, Yang F, Zhou Y, Xue Y. Incidence and risk factors for myelofibrotic transformation among 272 Chinese patients with JAK2-mutated polycythemia vera. Am J Hematol. 2015;90(12):1116-21.

Iurlo A, Cattaneo D, Bucelli C, Baldini L. New perspectives on polycythemia vera: From diagnosis to therapy. Int J Mol Sci. 2020;21(16):5805.

Grunwald MR, Stein BL, Boccia R V., Oh ST, Paranagama D, Parasuraman S, et al. Clinical and Disease Characteristics from REVEAL at Time of Enrollment (baseline): Prospective Observational Study of Patients with Polycythemia Vera in the United States. Clin Lymphoma Myeloma Leuk. 2018 ;18(12):788-795.

Tefferi A, Elliott M. Thrombosis in myeloproliferative disorders: Prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost. 2007;33 (4):313-20.

Cuthbert D, Stein BL. Polycythemia vera-associated complications: Pathogenesis, clinical manifestations, and effects on outcomes. J Blood Med. 2019;10(4):359-371.

Bai J, Ai L, Zhang L, Yang F, Zhou Y, Xue Y. Incidence and risk factors for the myelofibrotic transformation among 272 Chinese patients with JAK2-mutated polycythemia vera. Am J Hematol. 2015;90(12):1116-21.

Serin, Dou MH, Ekinci Ö, Akgün Çalyan G, Batürk A, Aras MR, et al. A Real-life Turkish Experience of Ruxolitinib in Polycythemia Vera. istanbul Med J. 2023;24(2):120–5.

Passamonti F, Giorgino T, Mora B, Guglielmelli P, Rumi E, Maffioli M, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017;31 (12):2726-2731.

Bonicelli G, Abdulkarim K, Mounier M, Johansson P, Rossi C, Jooste V, et al. Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: A population-based study of 327 patients. Br J Haematol. 2013;160 (2):251–4.

Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117 (10):755–61.